- Home
- SNAL vs RNXT Comparison
SNAL vs RNXT Comparison
Compare SNAL & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- RNXT
- Stock Information
- Founded
- SNAL 2000
- RNXT 2012
- Country
- SNAL United States
- RNXT United States
- Employees
- SNAL N/A
- RNXT N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SNAL Technology
- RNXT Health Care
- Exchange
- SNAL Nasdaq
- RNXT Nasdaq
- Market Cap
- SNAL 40.0M
- RNXT 37.6M
- IPO Year
- SNAL 2022
- RNXT 2021
- Fundamental
- Price
- SNAL $1.01
- RNXT $1.06
- Analyst Decision
- SNAL
- RNXT Strong Buy
- Analyst Count
- SNAL 0
- RNXT 2
- Target Price
- SNAL N/A
- RNXT $7.00
- AVG Volume (30 Days)
- SNAL 44.7K
- RNXT 116.6K
- Earning Date
- SNAL 05-19-2025
- RNXT 05-15-2025
- Dividend Yield
- SNAL N/A
- RNXT N/A
- EPS Growth
- SNAL N/A
- RNXT N/A
- EPS
- SNAL 0.05
- RNXT N/A
- Revenue
- SNAL $84,467,047.00
- RNXT $43,000.00
- Revenue This Year
- SNAL $21.96
- RNXT $4,755.81
- Revenue Next Year
- SNAL $22.77
- RNXT $187.93
- P/E Ratio
- SNAL $20.49
- RNXT N/A
- Revenue Growth
- SNAL 38.69
- RNXT N/A
- 52 Week Low
- SNAL $0.52
- RNXT $0.75
- 52 Week High
- SNAL $3.42
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- SNAL 45.83
- RNXT 60.35
- Support Level
- SNAL $0.98
- RNXT $1.02
- Resistance Level
- SNAL $1.08
- RNXT $1.09
- Average True Range (ATR)
- SNAL 0.09
- RNXT 0.05
- MACD
- SNAL 0.02
- RNXT 0.01
- Stochastic Oscillator
- SNAL 48.15
- RNXT 80.00
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.